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the osteoarthritis process, on the control of TGFI~ receptor II and 
Smad7 expression in articular chondrocytes. 
Methods: Primary cultures of Human Articular Chondrocytes 
(HAC) were treated with IL-11~ and TGFI~ effect was investigated. 
TGFl~-induced gene expression was analyzed through PAl-1 and 
3TP-Lux induction and TGFI~ signaling by R-Smad phosphoryla- 
tion and I-Smad expression. Type II TGFI~ receptor (TbRII) protein 
and mRNA expression were measured by Western-Blot and real- 
time RT-PCR. Transient transfections of human TbRII promoter 
constructs were performed to delineate the DNA sequences that 
mediate the IL-11~ effect. Experiments were also performed to 
overexpress or inhibit transcription factors involved in that reg- 
ulation. 
Results: We showed that IL-11~ pretreatment inhibits TGFI~- 
induced gene expression. Moreover, IL-11~ caused a dramatic de- 
crease of TI~RII at mRNA and protein level. TGFI~ signaling was 
also affected since IL-11~ inhibits TGFl~-induced Smad2/3 phos- 
phorylation and up regulates Smad7. In addition, we showed that 
the effect of IL-1 on TI~RII gene expression was mediated through 
a minimal core promoter that contains putative binding sites for 
NF-KB, Ets and AP-4 transcription factors. Overexpression and 
inhibition of these factors suggest that they cooperate to induce 
the IL-11~ effect. 
Conclusion: IL-11~ impairs TGFI~ signaling through TI~RII down- 
regulation and Smad 7 upregulation. This could explain the re- 
duced responsiveness of articular chondrocytes to TGFI~ during 
the late stages of OA process. 
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Aim: To investigate the mechanisms associated with the syner- 
gistic stimulation of aggrecan degradation by IL-I~ and Onco- 
statin M (OSM) in human articular cartilage and to measure OSM 
levels in synovial fluids (SF) obtained from patients with joint in- 
jury or arthritis. 
Methods: Normal human articular cartilage was obtained from 
autopsy and SF were obtained with informed consent and used 
under the approval of the institutional review board. Cartilage ex- 
plants were incubated with IL-I~ (20-100 ng/ml), OSM (10-50 
ng/ml), or the combination and analyzed for aggrecan degra- 
dation. Aggrecanase production was measured using a human 
articular chondrocyte cell-based enzymatic assay and a neoepi- 
tope ELI SA. To identify specific proteases impacted by IL-1 ~ and 
OSM, human chondrocytes derived from 4 donors were used to 
examine the effects on gene expression of ADAMTS-4, ADAMTS- 
5, MMP-9, and MMP-13 by RT PCR after 6 and 24 hours. OSM 
concentrations in OA SFs were analyzed using an ELISA devel- 
oped at GSK using a monoclonal anti-human OSM. 
Results: . In human articular cartilage explants, the combina- 
tion of IL-I~ and OSM caused a synergistic stimulation of aggre- 
can degradation in a concentration dependent manner, compared 
to IL-I~ treatment alone. In a human chondrocyte-based aggre- 
canase assay, IL-I~ or OSM alone had minimal effects, but the 
combination resulted in a synergistic stimulation of aggrecanase 
production. The synergistic effects by IL-1 and OSM on both car- 
tilage aggrecan degradation and aggrecanase production were 
completely blocked by the aggrecanase inhibitor. 
I L-I~ and OSM had differential effects on protease expression. 
Both cytokines alone induced ADAMTS-4 and MMP-13 expres- 
sion. IL-I~ but not OSM induced MMP-9 expression, and neither 
had an appreciable im pact on ADAMTS-5 expression either alone 
or in combination. The combination of IL-I~ and OSM had an ad- 
ditive effect on MMP-9 and MMP-13, and caused a synergistic 
stimulation of ADAMTS4 expression. 
SFs from 46 OA subjects were analyzed using an OSM ELISA, 
and 33 SF samples had detectable levels (limit of detection: 16 
pg/ml) of OSM. Several SF samples contained OSM at high levels 
(> 200pg/ml), and OSM concentrations of > 1000 pg/ml were 
detected in three samples. 
Conclusion: Synergistic stimulation of aggrecan degradation in 
human cartilage explants by IL-I~ and OSM is associated with a 
specific and synergistic induction of ADAMTS-4. Significant levels 
of OSM were detected in several SF samples from patients with 
joint injury. Together, these data support a role for OSM in OA. 
P289 
PROSTAGLANDIN E2 EXERTS CATABOLIC EFFECTS IN 
OA CARTILAGE: EVIDENCE FOR SIGNALING VIA THE 
Ep4 RECEPTOR 
M Attur, M Dave, J Patel, MH Pillinger, SB Abramson 
Division of Rheumatology, NYU School of Medicine, 
NYU-Hospital for Joint Diseases, New York, NY 
Purpose: OA cartilage explants spontaneously produce multi- 
ple cyclooxygenase and lipoxygenase products (including PGE2, 
PGD2, LTB4). PGE2, the predominant eicosanoid produced, sig- 
nals via four G-protein-coupled receptors (EP1 -EP4). In these 
studies we investigated the expression of EP receptors and ef- 
fects of PGE2 and the EP4 antagonist (A23858) on chondrocyte 
metabolism. 
Methods: Cartilage explants were prepared from OA patients 
undergoing joint replacement surgery. In selected experiments 
chondrocytes were isolated using collagenase digestion and cul- 
tured in alginate beads. The expression of PGE2 receptors (EPs) 
was analyzed using microarray and Real time-PCR. 
Results: Transcripts for all four EP receptors were expressed in 
both normal and OA chondrocytes. However, the EP4 receptor 
was upregulated (2-3-fold) in OA compared to normal. The addi- 
tion of PGE2 (0.1-10uM) exerted the following deleterious effects: 
1) PGE2 inhibited proteoglycan synthesis (35S incorporation) by 
chondrocyte cultures to levels of 75% control (p<0.01). The po- 
tency of inhibition was comparable to that of IL-lb, and the in- 
hibitory effects of the combination of IL-lb plus PGE2 (10uM) 
were additive; 2) PGE2 induced the production of LTB4, which 
itself exerted independent catabolic actions; 3) PGE2 induced 
the production of pro-MMP-13, IL-6 and IL-8. To examine the 
effects of endogenous PGE2 produced in response to IL-1, we 
performed experiments in the presence or absence of the COX- 
2 inhibitor, celecoxib. The addition of IL-1 reduced chondrocyte 
proteoglycan synthesis to 45% of control values; pretreatment 
with 2uM celecoxib, which inhibited IL-1 induced PGE2 produc- 
tion by >80%, reversed IL-1 dependent inhibition of proteoglycan 
synthesis from 45% to 77% of control values (p<0.01). We next 
performed experiments to determine whether these "catabolic ef- 
fects" of PGE2 were due to signaling via EP4 receptor, which we 
showed to be upregulated in OA chondrocytes. Addition of EP4 
specific antagonist A23858 (10uM): a) reversed the capacity of 
exogenous PGE2 to inhibit proteoglycan synthesis, b) inhibited 
PGE2 dependent production of MMP-13, and c) blocked the ef- 
fects of endogenously produced PGE2, attenuating the capacity 
of IL-1 to inhibit proteoglycan synthesis. 
